Cavernomas A Randomised Effectiveness (CARE) pilot trial, to address the effectiveness of active treatment (with neurosurgery or stereotactic radiosurgery) versus conservative management in people with symptomatic brain cavernoma The pros and cons of medical management versus medical and surgical management are finely balanced. The most reliable way of finding out which management is best is to do a randomised trial, in which suitable patients are allocated to medical management or medical and surgical management at random. This has never been done with cavernomas, and this was the top priority identified by a Priority Setting Partnership for cavernoma. Image Chief Investigator: Prof Rustam Al-Shahi Salman Number and location of participating sites (by region/ country): 42 sites - UK and Republic of Ireland EudraCT number: n/a ISRCTN number: 41647111 Funder: National Institute for Health Research Health Technology Assessment programme Start and End date Of grant award: September 2020 Of recruitment: April 2023 Current Status: Recruiting Trial Website: The Care Study Email: care.trial@ed.ac.uk UK GDPR Privacy Statement: As part of the PIS Sponsor: Accord, https://www.accord.scot/ Chief Investigator: Prof Rustam Al-Shahi Salman, CCBS, Chancellor’s Building, 49 Little France Crescent, Edinburgh Trial Manager: Dr Laura Forsyth, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh BioQuarter, 5-7 Little France Road, Edinburgh EH16 4UX ECTU involvement: Trial Management, Statistics, Health Economics, Database and randomisation service This article was published on 2024-09-24
